Get the Stockscreener App
2.55
2.67%
-0.07
After Hours:
2.55
Akebia Therapeutics Inc stock is traded at $2.55, with a volume of 5.72M.
It is down -2.67% in the last 24 hours and up +50.00% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$2.62
Open:
$2.62
24h Volume:
5.72M
Relative Volume:
1.41
Market Cap:
$641.37M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-9.1071
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
+4.08%
1M Performance:
+50.00%
6M Performance:
+31.44%
1Y Performance:
+91.73%
1-Day Range:
$2.54
$2.77
1-Week Range:
$2.25
$2.90
52-Week Range:
$0.80
$2.90
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.55 | 641.37M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics: Q1 Earnings Snapshot - New Haven Register
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... - Yahoo Finance
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and Strategic Market Penetration - GuruFocus
Akebia Therapeutics Reports Strong Q1 2025 Performance - TipRanks
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Akebia Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Akebia Therapeutics, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Akebia Therapeutics (AKBA) Sees Strong Q1 Revenue Growth Fueled by Vafseo - GuruFocus
Akebia projects Vafseo rollout to double patient access by Q4 2025 - MSN
Akebia Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Akebia Therapeutics beats Q1 2025 estimates, stock surges - Investing.com
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Akebia (AKBA) Surpasses Revenue Expectations with Strong Vafseo Debut | AKBA Stock News - GuruFocus
Akebia Therapeutics Inc Q1 2025 Earnings: EPS of $0.04, Revenue Surges to $57.3 Million, Beating Estimates - GuruFocus
Akebia Therapeutics, Inc. SEC 10-Q Report - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result - Yahoo Finance
Akebia Therapeutics Announces Multiple Positive Business Updates - ADVFN
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise - simplywall.st
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - ADVFN
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Expands Team: Grants $2.41 Stock Options to 8 New Strategic Hires - Stock Titan
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Akebia Therapeutics, Inc. Announces First Quarter 2025 Financial Results Release and Conference Call Details - Nasdaq
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights - The Manila Times
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business ... - Bluefield Daily Telegraph
Akebia (AKBA) Secures Strong Position with Vafseo Launch for Ane - GuruFocus
Leerink raises Akebia stock to outperform with $7 target By Investing.com - Investing.com Canada
Leerink Partners Initiates Coverage of Akebia Therapeutics (AKBA) with Outperform Recommendation - Nasdaq
Akebia (AKBA) Secures Strong Position with Vafseo Launch for Anemia Treatment | AKBA Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - ADVFN
Lobbying Update: $45,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock - Barchart.com
US High Growth Tech Stocks to Watch in 2023 - Yahoo Finance
Akebia Therapeutics : Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones - MarketScreener
Akebia Therapeutics gets EU positive recommendation for Xoanacyl - MSN
Akebia Therapeutics Announces Positive Opinion of European - GlobeNewswire
EMA panel endorses Akebia’s kidney disease treatment By Investing.com - Investing.com Australia
EMA panel endorses Akebia’s kidney disease treatment - Investing.com India
Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment - MarketScreener
Akebia Therapeutics' (AKBA) Xoanacyl Receives EMA Panel Endorsem - GuruFocus
Akebia says kidney drug endorsed in EU (AKBA:NASDAQ) - Seeking Alpha
Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months - MarketScreener
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):